Why integrin as a primary target for imaging and therapy.
about
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3Graphene: The Missing Piece for Cancer Diagnosis?Nanotheranostics for personalized medicineQuantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue modelEvaluation of Tc-99m-3PRGD2 Integrin Receptor Imaging in the Differential Diagnosis of Breast Lesions and Comparison With Mammography.Nanoparticles for Improving Cancer Diagnosis.Dual-functional, receptor-targeted fluorogenic probe for in vivo imaging of extracellular protease expressionsDynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe.Application of (68)Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke.PET and MR imaging of neuroinflammation in hepatic encephalopathy.Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using ⁶⁸Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort studyA Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer3D Fusion Framework for Infarction and Angiogenesis Analysis in a Myocardial Infarct Minipig Model99mTc-3P4-RGD2 scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI.Functional characterization of late outgrowth endothelial progenitor cells in patients with end-stage renal failure.Podosomes in adhesion, migration, mechanosensing and matrix remodeling.Integrin Targeted Imaging and Therapy.Targeted nanoprobes reveal early time point kinetics in vivo by time-resolved MRINanomedical engineering: shaping future nanomedicines.In vivo volumetric photoacoustic molecular angiography and therapeutic monitoring with targeted plasmonic nanostars.Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapyNew Methods for Labeling RGD Peptides with Bromine-76.Imaging tumor endothelial marker 8 using an 18F-labeled peptide.Lymphatic imaging: focus on imaging probes.Protein and peptide probes for molecular imagingRemodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression.Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in miceTrackable and Targeted Phage as Positron Emission Tomography (PET) Agent for Cancer Imaging.Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal MetastasesPET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2.Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model.VEGF-loaded graphene oxide as theranostics for multi-modality imaging-monitored targeting therapeutic angiogenesis of ischemic muscle.Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET ImagingTargeting Integrin-Dependent Adhesion and Signaling with 3-Arylquinoline and 3-Aryl-2-Quinolone Derivatives: A new Class of Integrin AntagonistsSynergistic enhancement of iron oxide nanoparticle and gadolinium for dual-contrast MRI.(18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases.Heat-induced-radiolabeling and click chemistry: A powerful combination for generating multifunctional nanomaterialsPreliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.
P2860
Q26771417-5650D2D7-36B9-4310-83FC-48D2084F9D5BQ26775114-865BE868-DE00-414E-9D5D-C67AECA275D5Q26851449-2869CFC1-DBF5-43CD-9D26-B6473D6B9DCAQ28729872-06DF6DC7-9D56-4906-9F9C-CFDA3E06B1A0Q30274889-78CFAE97-5CC1-41B1-93BD-19843DD17304Q30442412-0396F810-A208-451B-9302-15B2B6076E23Q30501344-437ABBBB-F48A-4983-B3F2-01654B34366EQ30524330-8D454AE4-4C7D-4F18-9585-9859D70EB555Q30832796-D96A3B42-12DE-4A27-806E-B13E64F45438Q30878855-53EBF7D8-F992-4CB9-945A-57DDED184D00Q33582972-BC54E958-AF44-488B-89D1-85B8876D613CQ33659257-255D095A-72BB-4C87-A9E9-18F8DFEFE8A5Q33767056-ED725AE6-204C-4104-938E-1B93929283CFQ33795447-A01764F2-10D6-4FC6-9C3C-711F160F56C1Q34252825-E1B40196-1DAB-49FE-9A31-DF2861392985Q34498304-65E5B3C7-04F0-4C86-A42C-29CB50FF1C4AQ34785129-FE6AF82D-E5CE-46EA-A901-3405B200DE93Q34786949-7B98C69E-3FCC-45C7-AE31-80B9C97623CDQ34974123-3F48E77B-F6FB-4D87-8D3E-B03028446405Q35019550-9770FB69-97C0-4BED-A3EE-6C3D8AEF9855Q35024494-0BEF96CC-774B-494F-8BC6-C027A5A3D708Q35194685-E658799E-3FB4-49D6-BBC6-E1E9B62FC5E3Q35224462-FFDCD89E-D483-4FBD-83D4-4D501EAF329EQ35436076-A756C940-6A90-4A25-96D7-2E86E69B8A4CQ35475925-9CDE86C4-27A7-4676-A560-93F931D869BAQ35501293-F87D40D9-FE1D-47BE-A39D-14E38C96E25AQ35538088-437229F9-6DBD-471A-AEE7-88509EA1AA88Q35629161-9515A237-E9AF-4D70-BFD5-EC121B7A7CB8Q35641927-B8E216E3-1B5E-445B-8FCD-247B3E4873D4Q35783096-A3AB8D24-47B1-4D02-8B95-A85039A4CD4DQ35868880-CF38FC76-37E1-498E-8E43-C2CC63F56068Q35869269-0C90A38A-8C12-4941-B773-B28E7BB5F30CQ36107186-B46C0582-DF19-4C1B-8D4D-FD26D11990FBQ36165427-8AEB987F-0101-4592-936B-CEC457FD2DCCQ36181664-38D2893D-2304-42BF-8969-31B23C62F10FQ36221121-46721B57-6746-46BC-9ECB-73B29A926032Q36223384-A9CDAD05-E900-4936-9646-3F61A3FA8606Q36225629-92603CE0-46C2-42E7-A0CF-02537EEC11F3Q36287535-6149A063-D9B4-4107-88E9-3DA48788A3DEQ36723768-563615B1-1FA3-4226-B368-B617B69ED743
P2860
Why integrin as a primary target for imaging and therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Why integrin as a primary target for imaging and therapy.
@ast
Why integrin as a primary target for imaging and therapy.
@en
Why integrin as a primary target for imaging and therapy.
@nl
type
label
Why integrin as a primary target for imaging and therapy.
@ast
Why integrin as a primary target for imaging and therapy.
@en
Why integrin as a primary target for imaging and therapy.
@nl
prefLabel
Why integrin as a primary target for imaging and therapy.
@ast
Why integrin as a primary target for imaging and therapy.
@en
Why integrin as a primary target for imaging and therapy.
@nl
P2860
P356
P1433
P1476
Why integrin as a primary target for imaging and therapy.
@en
P2860
P356
10.7150/THNO/V01P0030
P577
2011-01-01T00:00:00Z